NO20053364L - CC-kjemokinmutanter mot leversykdommer. - Google Patents

CC-kjemokinmutanter mot leversykdommer.

Info

Publication number
NO20053364L
NO20053364L NO20053364A NO20053364A NO20053364L NO 20053364 L NO20053364 L NO 20053364L NO 20053364 A NO20053364 A NO 20053364A NO 20053364 A NO20053364 A NO 20053364A NO 20053364 L NO20053364 L NO 20053364L
Authority
NO
Norway
Prior art keywords
liver disease
mutants
chemokine mutants
chemokine
gag
Prior art date
Application number
NO20053364A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053364D0 (no
Inventor
Amanda Proudfoot
Maureen Ajuebor
Mark Swain
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20053364D0 publication Critical patent/NO20053364D0/no
Publication of NO20053364L publication Critical patent/NO20053364L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20053364A 2002-12-23 2005-07-11 CC-kjemokinmutanter mot leversykdommer. NO20053364L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02102885 2002-12-23
EP03077237 2003-07-17
PCT/EP2003/051090 WO2004062688A2 (en) 2002-12-23 2003-12-22 Use of cc-chemokine mutants against liver diseases

Publications (2)

Publication Number Publication Date
NO20053364D0 NO20053364D0 (no) 2005-07-11
NO20053364L true NO20053364L (no) 2005-07-11

Family

ID=32715005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053364A NO20053364L (no) 2002-12-23 2005-07-11 CC-kjemokinmutanter mot leversykdommer.

Country Status (10)

Country Link
US (1) US7476381B2 (de)
EP (1) EP1575608B1 (de)
JP (1) JP2006514699A (de)
AT (1) ATE394117T1 (de)
AU (1) AU2003302755B2 (de)
CA (1) CA2507008A1 (de)
DE (1) DE60320848D1 (de)
ES (1) ES2305573T3 (de)
NO (1) NO20053364L (de)
WO (1) WO2004062688A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051781A1 (en) * 2005-10-31 2007-05-10 Laboratoires Serono S.A. Novel cxc-chemokine antagonists
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
US8632982B2 (en) * 2009-05-21 2014-01-21 Institute For Systems Biology Biomarkers for liver injury
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AU4561497A (en) 1996-09-25 1998-04-17 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
AU2001292301A1 (en) * 2000-10-11 2002-04-22 Daiichi Pharmaceutical Co., Ltd. Novel drugs for liver diseases
EP1458756B1 (de) * 2001-12-17 2009-01-28 Laboratoires Serono SA Chemokine mutanten, die als chemokine antagonisten wirken

Also Published As

Publication number Publication date
EP1575608A2 (de) 2005-09-21
JP2006514699A (ja) 2006-05-11
DE60320848D1 (de) 2008-06-19
ES2305573T3 (es) 2008-11-01
NO20053364D0 (no) 2005-07-11
EP1575608B1 (de) 2008-05-07
AU2003302755B2 (en) 2009-01-08
AU2003302755A1 (en) 2004-08-10
US20060228327A1 (en) 2006-10-12
US7476381B2 (en) 2009-01-13
CA2507008A1 (en) 2004-07-29
WO2004062688A2 (en) 2004-07-29
WO2004062688A3 (en) 2004-09-16
ATE394117T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DK0674641T3 (da) Pyrrolopyrimidiner som CRF-antagonister
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
EA199800119A1 (ru) Ингибиторы адгезии клеток
PT1230375E (pt) Inibicao de expressao genica com arncd
AU2003270117A1 (en) Al-Cu ALLOY WITH HIGH TOUGHNESS
EA200301248A1 (ru) Применение ингибиторов il-18 для лечения или предупреждения сепсиса
IT8522532A0 (it) Ne per gomme vulcanizzabili medianaddittivi coadiuvanti di lavoraziote perossidi.
ES2192839T3 (es) Timosina beta 4 oxidada.
WO2002060374A3 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2002358390A1 (en) Novel compounds
EP1895017A3 (de) Verwendung von A33-Antigenen und Jam-it
NO20044898L (no) Nye etonogestrel estere
DK1051395T3 (da) N-hydroxyformamidderivater
NO20053364D0 (no) CC-kjemokinmutanter mot leversykdommer.
EE200100478A (et) Vahend artriitilise haiguse raviks
SE0302304D0 (sv) Novel compounds
WO2002098346A3 (en) Method and pharmaceutical composition for the treatment of multiple sclerosis
ECSP045297A (es) Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?
NO20031525D0 (no) Kjemokinmutanter i behandlingen av multippel sklerose
ITTO20030832A1 (it) Struttura di tubazione del carburante in veicolo di piccole dimensioni.
DE602004015794D1 (de) Metalloxid-formulierungen
ATE421974T1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
MX2007000046A (es) Compuestos, composiciones y metodos de imidazolo relacionados para su uso.
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
EA200500878A1 (ru) Кальцилитические соединения

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application